Johnson & Johnson to buy Auris Health for $3.4 billion
Health products company Johnson & Johnson buys robotics firm Auris Health.
Johnson & Johnson will buy Auris Health, a robotics surgery firm. The health product company’s purchase is worth $3.4 billion in cash.
Why did Johnson & Johnson buy Auris Health?
Johnson & Johnson is the world’s largest health product producer. Auris makes robotic surgery products to assist doctors and has been valued at $2.1 billion. The pharmaceuticals giant is buying the startup to help expand into health technology.
‘This acquisition will accelerate Johnson & Johnson’s entry into robotics with potential for growth and expansion into other interventional applications,’ said Johnson & Johnson in a statement.
Ashley McEnvoy, Johnson & Johnson group chair of consumer medical devices, also explained the purpose of the purchase of Auris Health.
‘In this new era of health care, we're aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer. Collectively, these technologies, together with our market-leading medical implants and solutions, create the foundation of a comprehensive digital ecosystem to help support the surgeon and patient before, during and after surgery,’ said McAvoy in a statement.
When will Johnson & Johnson’s purchase of Auris Health be complete?
The purchase of Auris should be completed by Johnson & Johnson by the end of the second quarter. Johnson & Johnson chief executive officer, (CEO), Alex Gorsky, predicts the company will further expand into the billion-dollar surgical instrument business this year and into 2020.
‘What we want to make sure is that we get out in a timely manner, but that we're also out in a manner that ensures we're competitive and ensures, ultimately, that we're making an even bigger difference in this area as we go forward,’ said Gorsky.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.